Solesence Stock Price, News & Analysis

Solésence (Nasdaq: SLSN), a leader in scientifically-driven healthcare solutions for beauty and life science categories, has scheduled its second quarter 2025 financial results announcement for Thursday, July 31, 2025, after market close.

The company will host a conference call and webcast on the same day at 4:00 p.m. CDT (5:00 p.m. EDT). The call will feature presentations from President & CEO Jess Jankowski and COO Kevin Cureton. Participants can access the event through the company's investor relations website or register for dial-in access.

Solésence (Nasdaq: SLSN), a healthcare solutions provider specializing in beauty and life science, has announced its upcoming inclusion in both the Russell 3000® and Russell 2000® Indexes, effective June 30, 2025. This milestone follows the company's recent Nasdaq uplisting and is part of the 2025 Russell indexes reconstitution.

The inclusion is based on FTSE Russell's objective market-capitalization rankings, which capture the 4,000 largest US stocks as of April 30. This development is particularly significant as approximately $10.6 trillion in assets are benchmarked against Russell US indexes, potentially increasing Solésence's visibility among institutional investors.

Solésence (NASDAQ: SLSN) has expanded its debt facilities through amendments to existing loan agreements, increasing its maximum borrowing capacity from $14.2 million to $23.0 million. The amendments, executed on May 27, 2025, also extend the maturity dates from October 1, 2025 to April 30, 2027. The enhanced financial flexibility will support strategic objectives including raw material procurement at favorable prices, improved packaging and product launch lead times, and increased support for brand partners. CEO Jess Jankowski emphasized that the expanded capacity and extended timeline will help scale operations and better serve brand partners.

Solésence (NASDAQ: SLSN) reported strong Q1 2025 financial results with revenue increasing 48% to $14.6 million compared to $9.9 million in Q1 2024. The company achieved record shipment volume, up 95% year-over-year, and increased production volume by 120%. However, gross margin declined to 23% from 36% due to one-time start-up costs related to a new strategic brand partner launch. Net income was breakeven compared to $0.9 million in Q1 2024. The company successfully uplisted to Nasdaq and expanded its intellectual property with new technology patents in Japan, South Korea, and Mexico. Management reported strong order momentum with current shipped and open orders exceeding $45 million, indicating continued sequential revenue growth.

Solésence (Nasdaq: SLSN), a leader in scientifically-driven health care solutions focusing on beauty and life science categories, has scheduled its first quarter 2025 financial results announcement and conference call.

Key Details:

• Results Release: Monday, May 5, 2025, after market close
• Conference Call Time: 4:00 p.m. CDT / 5:00 p.m. EDT
• Key Speakers: Jess Jankowski (President & CEO) and Kevin Cureton (Chief Operating Officer)

Participants can access the conference call through multiple channels:

• Webcast: Available via media server link
• Dial-in: Registration required for personalized PIN
• Company Website: Accessible through investor relations page

Interested parties are advised to join the call at least five minutes before the start time. The company has provided convenient registration options, including an automatic dial-out feature once the conference begins.